文献速递肿瘤 PET/CT神经核医学

新型68Ga标记双碘氨基酸生长抑素类似物用于SST2和SST5双靶向显像

A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting.
PubMed 文献 · EJNMMI Res · 2020-08-05

本研究开发了携带两个碘代氨基酸的68Ga标记生长抑素类似物DOTA-ST8950,临床前评估其靶向生长抑素受体SST2和SST5的性能。体外实验显示其对SST2和SST5亲和力高于DOTA-NOC,去碘类似物DOTA-ST8951丧失亲和力;体内PET/CT可清晰显示SST2和SST5双瘤模型,肿瘤摄取与DOTA-NOC相当,但肝脏摄取仍是临床转化挑战。

要点

  • 68Ga-DOTA-ST8950对SST2和SST5亲和力高于DOTA-NOC,去碘后亲和力丧失。
  • 体内SST2和SST5肿瘤摄取与68Ga-DOTA-NOC相当,双瘤模型PET/CT对比度高。
  • 肝脏摄取较高,是临床转化的主要挑战。

核心结论

  • 68Ga-DOTA-ST8950具有用于SST2和SST5表达肿瘤PET显像的潜力,肿瘤摄取与临床使用的68Ga-DOTA-NOC相当,但肝脏摄取高限制临床转化。
  • 碘代氨基酸取代对维持对SST2和SST5的亲和力至关重要,去碘类似物DOTA-ST8951丧失对两种受体的亲和力。

研究设计与样本

  • 临床前体外与体内研究,比较DOTA-ST8950、去碘DOTA-ST8951及参照化合物DOTA-TATE和DOTA-NOC。
  • 体外评估亲和力、cAMP蓄积和内化率;体内在SST2和SST5双瘤移植模型中进行生物分布与PET/CT显像。

主要发现

  • natGa-DOTA-ST8950对SST2和SST5的IC50(95%CI)分别为0.32(0.20-0.50)nM和1.9(1.1-3.1)nM,低于natGa-DOTA-NOC的0.70(0.50-0.96)nM和3.4(1.8-6.2)nM。
  • natGa-DOTA-ST8951丧失对SST2和SST5的亲和力。
  • natGa-DOTA-ST8950诱导SST2介导cAMP蓄积的EC50为0.46(0.23-0.92)nM,与natGa-DOTA-TATE的0.47(0.15-1.5)nM相当,略优于natGa-DOTA-NOC的0.59(0.18-1.9)nM。
  • [67Ga]Ga-DOTA-ST8950在SST2表达细胞中4小时的内化率为12.4±1.6%,与[67Ga]Ga-DOTA-NOC的16.6±2.2%相似(p=0.0586)。
  • 体内[68Ga]Ga-DOTA-ST8950在SST2和SST5肿瘤中的摄取分别为26±8和15±6 %IA/g,与[68Ga]Ga-DOTA-NOC的30±8和12±5 %IA/g相当(1小时p.i.,p=0.4630和p=0.3282)。

临床怎么用

  • 68Ga-DOTA-ST8950有望用于同时表达SST2和SST5的神经内分泌肿瘤PET显像,但需解决肝脏高摄取问题后方可临床转化。

局限性

  • 肝脏摄取较高,是临床转化的挑战。
  • 研究为临床前评估,尚未在人体中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Somatostatin receptor (SST) targeting, specifically of the subtype 2 (SST2), with radiolabeled somatostatin analogs, is established for imaging and treatment of neuroendocrine tumors. Owing to the concomitant and heterogeneous expression of several subtypes on the same tumor, analogs targeting more subtypes than SST2 potentially target a broader spectrum of tumors and/or increase the uptake of a given tumor. The analog ST8950 ((4-amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2), bearing 2 iodo-amino acids, exhibits sub-nanomolar affinity to SST2 and SST5. We report herein the development and preclinical evaluation of DOTA-ST8950 labeled with 68Ga, for imaging SST2- and SST5-expressing tumors. Comparative in vitro and in vivo studies were performed with the de-iodinated DOTA-ST8951 ((4-amino)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2) and with the reference compounds DOTA-TATE (SST2 selective) and DOTA-NOC (for SST2 and SST5). RESULTS: Compared with natGa-DOTA-NOC, natGa-DOTA-ST8950 exhibited higher affinity to SST2 and SST5 (IC50 (95%CI), nM = 0.32 (0.20-0.50) and 1.9 (1.1-3.1) vs 0.70 (0.50-0.96) and 3.4 (1.8-6.2), respectively), while natGa-DOTA-ST8951 lost affinity for both subtypes. natGa-DOTA-ST8950 had the same potency for inducing SST2-mediated cAMP accumulation as natGa-DOTA-TATE and slightly better than natGa-DOTA-NOC (EC50, nM = 0.46 (0.23-0.92) vs 0.47 (0.15-1.5) vs 0.59 (0.18-1.9), respectively). [67Ga]Ga-DOTA-ST8950 had a similar internalization rate as [67Ga]Ga-DOTA-NOC in SST2-expressing cells (12.4 ± 1.6% vs 16.6 ± 2.2%, at 4 h, p = 0.0586). In vivo, [68Ga]Ga-DOTA-ST8950 showed high and specific accumulation in SST2- and SST5-expressing tumors, comparable with [68Ga]Ga-DOTA-NOC (26 ± 8 vs 30 ± 8 %IA/g, p = 0.4630 for SST2 and 15 ± 6 vs 12 ± 5 %IA/g, p = 0.3282, for SST5, 1 h p.i.) and accumulation in the SST-positive tissues, the kidneys and the liver. PET/CT images of [68Ga]Ga-DOTA-ST8950, performed in a dual HEK-SST2 and HEK-SST5 tumor xenografted model, clearly visualized both tumors and illustrated high tumor-to-background contrast. CONCLUSIONS: [68Ga]Ga-DOTA-ST8950 reveals its potential for PET imaging SST2- and SST5-expressing tumors. It compares favorably with the clinically used [68Ga]Ga-DOTA-NOC in terms of tumor uptake; however, its uptake in the liver remains a challenge for clinical translation. In addition, this study reveals the essential role of the iodo-substitutions in positions 1 and 3 of [68Ga]Ga-DOTA-ST8950 for maintaining affinity to SST2 and SST5, as the de-iodinated [68Ga]Ga-DOTA-ST8951 lost affinity for both receptor subtypes.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Mansi R, Abid K, Nicolas GP, et al. A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting. EJNMMI Res. 2020. PMID: 32757150. doi:10.1186/s13550-020-00677-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。